Gainers

• Nuwellis (NASDAQ:NUWE) shares increased by 166.5% to $5.73 during Tuesday's pre-market session. The company's market cap stands at $1.9 million.
• Genenta Science (NASDAQ:GNTA) stock increased by 63.07% to $2.12. The market value of their outstanding shares is at $30.4 million.
• BiomX (AMEX:PHGE) shares increased by 62.43% to $6.66. The market value of their outstanding shares is at $6.2 million.
• USBC (AMEX:USBC) stock moved upwards by 45.48% to $0.82. The market value of their outstanding shares is at $219.3 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 14.35% to $0.09. The company's market cap stands at $10.5 million.
• Savara (NASDAQ:SVRA) shares moved upwards by 12.45% to $6.5. The market value of their outstanding shares is at $1.1 billion.

Losers

• Alignment Healthcare (NASDAQ:ALHC) shares declined by 15.2% to $20.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.7 billion.
• Humana (NYSE:HUM) stock decreased by 15.02% to $224.04. The company's market cap stands at $31.7 billion.
• UnitedHealth Group (NYSE:UNH) shares declined by 13.84% to $302.99. The company's market cap stands at $318.5 billion. As per the press release, Q4 earnings came out today.
• CVS Health (NYSE:CVS) stock declined by 11.51% to $74.22. The market value of their outstanding shares is at $106.4 billion.
• BioAtla (NASDAQ:BCAB) stock declined by 10.02% to $0.32. The company's market cap stands at $22.6 million.
• Check-Cap (NASDAQ:MBAI) stock decreased by 9.82% to $2.85. The company's market cap stands at $19.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.